High materiality8/10
Latigo Biotherapeutics initiated with a Buy at Goldman Sachs
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Goldman Sachs initiates LTGO with a Buy rating and targets $73 on LTGO; current price $22.02.
- Goldman Sachs initiates LTGO with Buy; target $73.
- Current price $22.02; potential upside to $73.
Key facts
- 01
Target: $73
- 02
Posted price: $22.02
- 03
Analyst firm: Goldman Sachs
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.